ArticleInternational journal of clinical and experimental medicine2015
Deregulation of decorin and FHL1 are associated with esophageal squamous cell carcinoma progression and poor prognosis.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Decorin: matrix-based pan-cancer tumor suppressor.Molecular and cellular biochemistry · 2025Review
- Research progress on the role of decorin in the development of oral mucosal carcinogenesis.Oncology research · 2025Review
- Role of four and a half LIM domain protein 1 in tumors (Review).Oncology letters · 2025Review
- FHL1: A novel diagnostic marker for papillary thyroid carcinoma.Pathology international · 2024Article
- Immortalization-upregulated protein promotes pancreatic cancer progression by regulating NPM1/FHL1-mediated cell-cycle-checkpoint protein activity.Cell biology and toxicology · 2023Article
- Expression and Predictive Significance of FHL1 and SLIT3 in Surgically Resected Lung Adenocarcinoma.Combinatorial chemistry & high throughput screening · 2023Article
- Oncosuppressive roles of decorin through regulation of multiple receptors and diverse signaling pathways.American journal of physiology. Cell physiology · 2022Review
- Plasma Levels of Decorin Increased in Patients during the Progression of Breast Cancer.Journal of clinical medicine · 2021Article
- Proteoglycans and their functions in esophageal squamous cell carcinoma.World journal of clinical oncology · 2021Review
- Study on the expression profile and role of decorin in the progression of pancreatic cancer.Aging · 2021Article
- Four and a half LIM domains protein 1 can be as a double-edged sword in cancer progression.Cancer biology & medicine · 2020Review
- Data-Driven Discovery of Extravasation Pathway in Circulating Tumor Cells.Scientific reports · 2017Article
- CCR7 enhances the angiogenic capacity of esophageal squamous carcinoma cells in vitro via activation of the NF-κB/VEGF signaling pathway.American journal of translational research · 2017Article
- Comprehensive investigation of proteoglycan gene expression in breast cancer: Discovery of a unique proteoglycan gene signature linked to the malignant phenotype.Proteoglycan researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the expression of FHL1 and Decorin in esophageal squamous cell carcinoma (ESCC) and its clinical significance. 82 ESCC tissues were evaluated by immunohistochemistry for the expression of FHL1 and Decorin. The role of the expression of FHL1 and Decorin in ESCC were statistically analyzed. The expression level of FHL1 and Decorin were reduced in malignant tissue samples in comparison to normal matched tissue (P < 0.05). It was also proved that the positive expressions of FHL1 and Decorin were associated with ESCC histological grade, lymph node metastasis, tumor stage and clinical stage (P < 0.05). In addition, the Kaplan-Meier survival curves revealed that the positive expressions of FHL1 and Decorin were associated with favorable prognosis in ESCC patients. Multivariate analysis showed that the positive expressions of FHL1 and Decorin were independent prognostic markers of overall survival of ESCC patients, respectively. The positive expressions of FHL1 and Decorin were associated with ESCC progression and good prognosis. Our results indicate that the positive expressions of FHL1 and Decorin were independent prognostic factors for patients with esophageal cancer, which might be potential valuable biomarkers for ESCC.
Indexed as
Identifiers
26885026PMC4723871W2411115950What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.